FDA accepts Novo Nordisk's resubmitted application for insulin drug

09 Apr 2015


The U.S. Food and Drug Administration has accepted a resubmitted application for Novo Nordisk’s key insulin drug, Tresiba, based on interim analysis data from a clinical trial.

Reuters


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story